Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3379-3385

  Tosoian, Jeffrey J ^a   Mamawala, Mufaddal ^a   Epstein, Jonathan I ^a   Landis, Patricia ^a   Wolf, Sacha ^a   Trock, Bruce J ^a   Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; COHORT ANALYSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK FACTOR; SENTINEL SURVEILLANCE; UNITED STATES; VERY ELDERLY; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SENTINEL SURVEILLANCE; UNITED STATES; WATCHFUL WAITING;

EID: 84944474830     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.5764     Document Type: Article

References (25)

1. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005
2. Moyer VA, Force USPST: Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 157: 120-134, 2012
3. Carter HB, Albertsen PC, Barry MJ, et al: Early detection of prostate cancer: AUA guideline. J Urol 190:419-426, 2013
4. Hayes JH, Barry MJ: Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence. JAMA 311:1143-1149, 2014
5. Hoffman KE, Niu J, Shen Y, et al: Physician variation in management of low-risk prostate cancer: A population-based cohort study. JAMA Intern Med 174:1450-1459, 2014
6. Dall'Era MA, Albertsen PC, Bangma C, et al: Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol 62:976-983, 2012
7. Womble PR, Montie JE, Ye Z, et al: Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 67:44-50, 2015
8. Klotz L, Vesprini D, Sethukavalan P, et al: Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272-277, 2015
9. Ganz PA, Barry JM, Burke W, et al: National Institutes of Health State-of-the-Science Conference: Role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 156:591-595, 2012
10. Epstein JI, Walsh PC, Carmichael M, et al: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374, 1994
11. Carroll PR, Parsons JK, Andriole G, et al: Prostate cancer early detection, version 1.2014. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 12:1211-1219, 2014
12. Umbehr MH, Platz EA, Peskoe SB, et al: Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. BJU Int 113: 561-567, 2014
13. Southern DA, Faris PD, Brant R, et al: KaplanMeier methods yielded misleading results in competing risk scenarios. J Clin Epidemiol 59:1110-1114, 2006
14. Centers for Disease Control and Prevention: National Death Index. http://www.cdc.gov/nchs/ndi.htm
15. Haffner MC, Mosbruger T, Esopi DM, et al: Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123:4918-4922, 2013
16. Eggener SE, Scardino PT, Walsh PC, et al: Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185:869-875, 2011
17. Schroder FH, Hugosson J, Roobol MJ, et al: Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027-2035, 2014
18. Bill-Axelson A, Holmberg L, Garmo H, et al: Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370:932-942, 2014
19. Bul M, Zhu X, Valdagni R, et al: Active surveillance for low-risk prostate cancer worldwide: The PRIAS study. Eur Urol 63:597-603, 2013
20. Newcomb LF, Brooks JD, Carroll PR, et al: Canary Prostate Active Surveillance Study: Design of a multi-institutional active surveillance cohort and biorepository. Urology 75:407-413, 2010
21. Welty CJ, Cowan JE, Nguyen H, et al: Extended follow-up and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol 193:807-811, 2015
22. Pierorazio PM, Walsh PC, Partin AW, et al: Prognostic Gleason grade grouping: Data based on the modified Gleason scoring system. BJU Int 111: 753-760, 2013
23. Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-213, 2012
24. Cooperberg MR, Broering JM, Carroll PR: Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117-1123, 2010
25. Sundi D, Ross AE, Humphreys EB, et al: African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: Should active surveillance still be an option for them? J Clin Oncol 31:2991-2997, 2013